Financial services company Fidelity Investments on Friday (December 20) divested a 1.3% stake in drug firm Granules India for ₹191 crore through open market transactions.

US-based Fidelity Investments, through its three arms — Fidelity India Fund, Dendana Invest Mauritius and Fidelity Funds – India Focus Fund, sold shares of Hyderabad-based Granules India through three separate block deals on the NSE.

As per the data, Fidelity Investments, through its affiliates offloaded 32 lakh shares or 1.32% stake in Granules India. The shares were disposed of at an average price of ₹596 apiece, taking the transaction value to ₹190.72 crore, as per the data on the National Stock Exchange (NSE).

Also Read: Granules India subsidiary receives USFDA nod for ADHD treatment drug

Aditya Birla Sun Life Mutual Fund (MF), Paulomi Ketankumar Doshi, Bandhan MF, Edelweiss MF, ITI MF, SBI Life Insurance and Kotak Mahindra Life Insurance Company acquired were the buyers of Granules India’s shares at the same price. Granules India’s shares on Friday fell 1.51% to close at ₹591 per piece on the NSE.

In a separate transaction on the BSE, BlackRock on Friday bought 4.51 lakh shares or 1.1% stake in Protean eGov Technologies for ₹90 crore through an open market transaction. As per the bulk deal data, BlackRock, through its affiliate iShares Cybersecurity and Tech ETF, purchased shares at an average price of ₹1,999.11 apiece, taking the deal value to ₹90.24 crore.

Details of the sellers of Protean eGov Technologies shares could not be identified on the BSE. On Friday, shares of Protean eGov Technologies rose 1.65% to settle at ₹2,005.65 per piece on the BSE.

Also Read: Granules India’s Gagillapur facility warrants regulatory action, the USFDA says